company background image
CLNN logo

Clene NasdaqCM:CLNN Stock Report

Last Price

US$0.43

Market Cap

US$54.6m

7D

0.09%

1Y

-62.7%

Updated

28 Mar, 2024

Data

Company Financials +

CLNN Stock Overview

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.

CLNN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Clene Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Clene
Historical stock prices
Current Share PriceUS$0.43
52 Week HighUS$1.22
52 Week LowUS$0.25
Beta0.48
1 Month Change0.094%
3 Month Change43.43%
1 Year Change-62.68%
3 Year Change-96.73%
5 Year Change-95.78%
Change since IPO-95.59%

Recent News & Updates

Recent updates

Clene slips 13% as lead asset fails in ALS study

Oct 03

Clene ALS therapy gets EMA panel backing for orphan drug status

Jul 19

Clene Inc.: A First Take

Apr 07

Shareholder Returns

CLNNUS BiotechsUS Market
7D0.09%0.9%0.4%
1Y-62.7%10.3%28.8%

Return vs Industry: CLNN underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: CLNN underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is CLNN's price volatile compared to industry and market?
CLNN volatility
CLNN Average Weekly Movement14.0%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: CLNN's share price has been volatile over the past 3 months.

Volatility Over Time: CLNN's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a84Rob Etheringtonhttps://clene.com

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution.

Clene Inc. Fundamentals Summary

How do Clene's earnings and revenue compare to its market cap?
CLNN fundamental statistics
Market capUS$54.58m
Earnings (TTM)-US$49.50m
Revenue (TTM)US$654.00k

83.5x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CLNN income statement (TTM)
RevenueUS$654.00k
Cost of RevenueUS$121.00k
Gross ProfitUS$533.00k
Other ExpensesUS$50.04m
Earnings-US$49.50m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.39
Gross Margin81.50%
Net Profit Margin-7,569.42%
Debt/Equity Ratio199.1%

How did CLNN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.